pSivida Announces FDA Acceptance For Filing of New Drug Application for Durasert

pSivida (NASDAQ:PSDV) a leader in the development of sustained release drug products and technologies, today announced that its New Drug Application (NDA) for Durasert three-year treatment for posterior segment uveitis has been accepted by the U.S. Food and Drug Administration (FDA) for filing.

As quoted in the press release:

“The FDA’s acceptance for review of our Durasert NDA submission is a major milestone for pSivida and we look forward to continuing to work with the FDA as they review our application,” commented Nancy Lurker, President and CEO.  “Given the high unmet medical need, we believe that Durasert, if approved, has the potential to become an important new treatment option for the thousands of patients suffering from posterior segment uveitis, the third leading cause of blindness.”

Click here to read the full press release.